Home › Funds › Rock Springs Capital Management LP › ZBIO
Rock Springs Capital Management LP position in ZBIO
ZENAS BIOPHARMA INC · Health Care
Rock Springs Capital Management LP reported holding 502,077 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$13.5M, representing 0.73% of its reported portfolio and ranking #44 among its reported holdings. Rock Springs Capital Management LP has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Rock Springs Capital Management LP's ZBIO position evolved
Rock Springs Capital Management LP first disclosed a stake in ZBIO in Q3 2024 at 878,667 shares (US$14.9M). The position peaked in Q4 2025 at 502,077 shares, worth US$18.2M. Across 9 filings, Rock Springs Capital Management LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 502,077 shares valued at US$13.5M. Notable position changes include a 27% trim in Q2 2025 (shares rose 129% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 878.67K | $14.87M | New |
| Q4 2024 | 878.67K | $7.20M | Hold |
| Q1 2025 | 878.67K | $6.94M | Hold |
| Q2 2025 | 640.47K | $6.21M | Reduce |
| Q3 2025 | 580.68K | $12.89M | Reduce |
| Q4 2025 | 502.08K | $18.23M | Reduce |
| Q1 2026 | 502.08K | $9.82M | Hold |
| Q2 2026 | 502.08K | $12.74M | Hold |
| Q3 2026 | 502.08K | $13.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 62 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M sh · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $64.41M · Q3 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M sh · $49.58M · Q3 2026
- Context Capital Management, LLC 31.05M sh · $39.70M · Q3 2026
- Graham Capital Management, L.P. 21.25M sh · $27.32M · Q3 2026
- EcoR1 Capital, LLC 789.50K sh · $21.29M · Q3 2026
- ArrowMark Colorado Holdings LLC 527.98K sh · $14.24M · Q3 2026
- NEXTBio Capital Management LP 426.74K sh · $11.51M · Q3 2026
More on Rock Springs Capital Management LP
FAQ
How long has Rock Springs Capital Management LP held ZBIO?
Rock Springs Capital Management LP has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Rock Springs Capital Management LP's current position in ZBIO?
As of Q3 2026, Rock Springs Capital Management LP holds 502.08K shares of ZBIO (ZENAS BIOPHARMA INC), valued at $13.54M, representing 0.73% of its reported portfolio and ranking #44.
Has Rock Springs Capital Management LP been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Rock Springs Capital Management LP held unchanged its position in ZBIO. The position peaked in Q4 2025 at 502.08K shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.